Abstract. Thymidine Phosphorylase (dThdPase) is the rate-tissues expressed high levels of DPD (median >70 U/mg limiting enzyme that metabolizes 5'-deoxy-5-fluorouridine protein), while high concentrations of the dThdPase were (5'-dFUrd, doxifluridine), an intermediate metabolite of expressed in esophageal, cervical, breast, and pancreatic capecitabine, to the active drug 5-fluorouracil (5-FUra), while cancers and hepatoma (median >150 U/mg protein). The dihydropyrimidine dehydrogenase (DPD) catabolizes 5-FUra dThdPase/DPD ratio, which was reported to correlate with to an inactive molecule. The susceptibility of tumors to the susceptibility of human cancer xenografts to capecitabine, fluoropyrimidines is reported to correlate with tumor levels was high in esophageal, renal, breast, colorectal, and gastric of these enzymes. To obtain some insight into the tumor cancers (median ratio of > 1.5). In any of these three parameters, types susceptible to fluoropyrimidine therapy, we measured the inter-patient DPD variability for each cancer type was expression levels of these two enzymes in various types of much larger than the DPD variability among cancer types; human cancer tissues (241 tissue samples) by the ELISA highest/lowest ratios for dThdPase, DPD, and dThdPase/DPD methods. DPD exists in all the cancer types studied, such were 10-321, 7-513, and 2-293, respectively. These results as bladder, breast, cervical, colorectal, esophageal, gastric, indicate that measurements of the three parameters, DPD, hepatic, pancreatic, prostate, and renal cancers. Among them, dThdPase and dThdPase/DPD, would be useful criteria for the cervical, hepatic, pancreatic, esophageal, and breast cancer selecting cancer patients suitable for fluoropyrimidine therapy rather than for selecting cancer types.
pyrimidine dehydrogenase (DPD) and thymidine Phos phorylase (dThdPase). DPD catabolizes 5-FUra to inactive molecule dihydrofluorouracil, and its expression level in tumors is reported to inversely correlate with the activity of 5-FUra in cancer patients (1) (2) (3) . In contrast, the tumor level of dThdPase is reported to correlate with the efficacy of 5'-deoxy-5-fluorouridine (5'-dFUrd) (4; Toi M, et al, Proc ASCO 16: abs. 481, 1997; Toi M, et al, Angiogenesis, in print), an intermediate metabolite of capecitabine (5) . dThdPase is the enzyme essential for the activation of capecitabine and 5'-dFUrd and preferentially exists in tumors (5) . Fox et al observed that breast cancer patients who have dThdPase positive-primary tumors responded well to subsequent adjuvant chemotherapy with CMF (4). Toi et al also indicated that patients with dThdPase positive breast cancer would receive survival benefits from subsequent adjuvant chemotherapy with 5'-dFUrd. In human cancer xenograft models, the susceptibility of human cancer xenografts to capecitabine correlated well with the dThdPase/DPD ratio in tumor tissue (6) . It is therefore of interest to find which types of cancer highly express dThdPase and DPD for selecting cancer types susceptible to fluoropyrimidine therapies.
Nishida et al established a convenient ELISA method for measuring dThdPase in cancer tissue (7) . The same group recently prepared monoclonal antibodies to human DPD and established an ELISA with them for measuring DPD (Hasegawa M, et al, 35th Annual Meeting of the Japan Society of Clinical Oncology, 1997). In the present study, we measured the expression levels of dThdPase and DPD in large numbers of human cancer tissues to get insight into identification of rational targets of fluoropyrimidine therapy. First, we confirmed that the DPD expression levels determined by the ELISA methods correlated well with those determined by a conventional enzyme activity assay. In addition, we observed that DPD exists in various types of cancer with large inter-patient variability. The potential usefulness of measuring dThdPase and DPD for selecting cancer patients who are likely to respond to fluoropyrimidine therapy is also discussed.
Materials and methods
Sample preparation for ELISA and enzyme activity assay. Tumor tissues were obtained from cancer patients in Japan as follows: 14 bladder cancer, 20 breast cancer, 25 cervical cancer, 20 colorectal cancer, 43 esophageal cancer, 29 gastric cancer, 31 hepatoma, 14 pancreatic cancer, 20 prostate cancer, and 25 renal cancer. None of tumor tissues had been treated with any chemotherapy. Each sample of tumor tissue was homo genized in 10-fold volume of 10 mM Tris-HCl buffer (pH 7.4) containing 15 mM NaCl, 1.5 mM MgCl 2 , and 50 uM potassium phosphate, and then centrifuged at 10,000 x g for 15 min. The supernatant was stored at -80°C until used. A portion of the supernatant was dialyzed overnight at 4°C in a buffer containing 20 mM potassium phosphate (pH 7.4) and 1 mM 2-mercaptoethanol, and then stored at -80°C until used for DPD enzyme activity assay. The protein concentration of the supernatant extracted from tumor tissues was determined using a DC Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA).
DPD ELISA. The DPD expression level was measured by a sandwich ELISA with two monoclonal antibodies (MoAbs) specific to human DPD. In brief, a 96-well microtiter plate (Nunc-immunoplate Maxisorp, Nunc, Roskilde, Denmark) was incubated at 4°C overnight with 10 ug/ml of the anti-DPD MoAb 4B9 in 10 mM phosphate-buffered saline solution (PBS, pH 7.6). The plate coated with the antibody was then incubated with 3% (w/v) skim milk in PBS (blocking buffer) for 2 h at 37°C. The plate was washed with diluted washing buffer (Kirkegaard & Perry Laboratories Inc., Gaitherburg, MD) and kept at 4°C with 0.05% sodium azide PBS (ELISA plate). The ELISA plate was then washed three times, following which test samples and a serially diluted solution of the DPD standard, which is a homogenate of the HT-3 human cancer xenograft in PBS containing 0.3% (w/v) skim milk (DPD diluent), were dispensed onto the ELISA. The plate was: a) incubated at 37°C for 1.5 h and then washed four times; b) incubated with the anti-DPD MoAb 3A5 at 2 ug/ml in a blocking buffer for 1.5 h at room temperature and washed four times; c) incubated with 1,000-fold diluted rat antimouse IgM (u.) conjugated with horseradish peroxidase (Zymed, So., San Francisco, CA) for 1 h at room temperature and washed four times; and d) incubated with a substrate solution containing 3,3',5,5'-tetramethylbenzidine (TMB) and H 2 0 2 (TMB microwell peroxidase substrate system, Kirkegaard & Perry Laboratories Inc., Gaitherburg, MD) for 10 min at room temperature. The peroxidase reaction was stopped by the addition of 1 M phosphate solution, and the amount of DPD sandwiched with the two MoAbs was estimated by measuring its absorbance at 450 nm with a plate reader (Model 3550, Bio-Rad Laboratories, Hercules, CA). The amount of DPD was calibrated with that measured for the standard solution. DPD levels in tumor tissues were expressed as U/mg protein, and one unit is equivalent to the amount of DPD protein that catabolizes 1 pmole of 5-FU per minute. The inter-assay precision of DPD ELISA was 2.5% inCV.
DPD standard protein.
A crude tissue extract of the HT-3 human cervical cancer xenograft was used as the standard DPD preparation. Male BALB/c nu/nu mice were obtained from SLC, Hamamatsu, Japan. A single cell suspension of the HT-3, which was purchased from the American Type Culture Collection, MD, USA, was inoculated subcutaneously into the athymic mice. When the tumor size reached about 1 cm 3 , tumor tissues were excised for preparation of the ELISA standard. The DPD concentration of the standard solution was determined by the ELISA with reference to DPD activity in the crude enzyme preparation of human PBMC.
DPD enzyme activity assay. DPD enzyme activity was measured by counting the radioactivity of the products formed from the substrate [6- 14 C] 5-FU (American Radiolabeled Chemicals Inc., St. Louis, MO) after its separation on a silica gel TLC plate. The mixture for the enzyme reaction (50 ul) contained 10 mM potassium phosphate (pH 8.0), 0.5 mM EDTA, 0.5 mM 2-mercaptoethanol, 2 mM dithiothreitol, 2.5 mM MgCl 2 , 250 [xM NADPH, 25 uM [6] [7] [8] [9] [10] [11] [12] [13] [14] C] 5-FU, and 25 ul of crude DPD enzyme. The reaction was carried out at 37°C for 30 min and then terminated by immersing the reaction tubes (0.5-rnl Eppendorf tubes) in a boiling water-bath for 30 min. During this boiling, more than 95% of [6- 14 C] FUH 2 is converted to FUPA or further on to FBAL. The reaction mixture was frozen at -20°C for at least 20 min before any further manipulations were undertaken. Proteins precipitated were removed by centrifugation, and then 10 pi of the supernatants were spotted onto silica gel TLC plates (Merck), which were pre-spotted with 5 JLXI of 10 mM 5-FU (Kyowa). The spots were developed in a solvent system comprising mixture of ethylacetate:isopropanoI:water (65:23:12, v/v/v) until the front of the solvent reached a distance of 10 cm from position spotted. To quantify the catalytic activity, the TLC plates were then exposed for 16-18 h with an imaging plate, BAS Ills (Fujix), and the signal corresponding to the enzyme reaction product was counted using an image analyzer, BAS 1000 (Fujix). To calibrate the inter-assay deviation, the DPD activity in the HT-3 tumor homogenate was measured as a standard in each assay. The inter-assay precision of DPD enzyme assay was 8.8% in CV.
dThdPase ELISA. Levels of dThdPase in tumor tissues were measured by an ELISA method as described elsewhere (7). dThdPase levels measured by a conventional enzyme activity assay correlated well with those measured by the ELISA method. The levels of dThdPase in tumor tissues were expressed as U/mg protein, where 1 U is the amount equivalent to 1 fig of 5-FU produced in an hour as an enzyme activity. The inter-assay precision of dThdPase ELISA was 8.6% in CV.
Statistical analysis. The statistical similarities of the correlation coefficient between DPD levels determined by the enzyme activity assay and ELISA and between DPD levels and dThdPase levels were compared with the Fisher's r to z trans formation test. Similarities were considered to be significant when the probability (p)-value was <0.05.
Results
We measured DPD levels in 241 human cancer tissues by an ELISA method specific for DPD and by a conventional enzyme reaction assay. The tissue samples included those from 14 bladder, 20 breast, 25 cervical, 20 colorectal, 43 esophageal, 29 gastric, 31 hepatic, 14 pancreatic, 20 prostate, and 25 renal cancer patients. Fig. 1 shows the DPD levels determined by the two assay methods, which correlated well with each other in every cancer type studied, although the levels measured by the ELISA are lower. Table I and Fig. 2 show the ranges of DPD expression levels in tumor tissues from each cancer type. The median levels of DPD expression were 1.5-5 times higher in cervical, hepatic, pancreatic, esophageal and breast cancers than in other types of cancer. However, the inter-patient variability in the DPD for any cancer type was much larger than the cancer-type DPD variability. The ratios of the highest to the lowest DPD levels ranged from 7 (pancreatic cancer) to 513 (cervical cancer). dThdPase levels in tumor tissues were also measured by an ELISA method specific for human dThdPase, because the levels measured by the ELISA and by an enzyme activity assay correlated well (7). Table II and Fig. 3 show that dThdPase was expressed in the tumor tissues. dThdPase was Figure 1 . Correlation between DPD levels determined by ELISA and by enzyme activity assay. DPD levels in various tumor tissues were determined by DPD ELISA and by DPD activity assay as described in Materials highly expressed in esophageal, cervical, breast, and pancreatic cancers and hepatoma, followed by renal, gastric and colorectal cancers, whereas it was expressed to a lesser extent in bladder and prostate cancers. However, the interpatient variability in the dThdPase levels was also much larger than the cancer-type variability for all the cancer types studied. Table III shows the ratios of dThdPase to DPD levels, the order of which is esophageal, renal, colorectal, breast, gastric, "dThdPase levels in various tumor tissues were determined by an ELISA, as described in Materials and methods. Max/min was the ratio of the dThdPase range.
"The ratios of tumor levels of dThdPase to that of DPD were determined as shown in Tables I and II . Max/min was the ratio of the range of the dThdPase/DPD ratio.
pancreatic, cervical, hepatic, bladder and prostate cancers. The individual patient differences in the tumor dThdPase/DPD ratios were also very large for any cancer type as compared with the cancer-type difference (Fig. 4) . We also analyzed the correlation between tumor levels of DPD and dThdPase, which indicated a positive correlation for some cancer types, such as colorectal, pancreatic, esophageal, bladder, cervical, hepatic, and gastric cancers (Table IV) .
Discussion
The present study measured DPD levels and dThdPase/DPD ratios in numbers of tumor tissues from patients with various types of cancer by using the DPD ELISA, which was recently established. DPD is reported to exist mainly in the liver among normal organs in humans (8) . We observed that either DPD enzyme activity or DPD protein also exists in tumor tissues of "The statistical similarities of the correlation coefficient between DPD levels and dThdPase levels were compared with the Fisher's r to z transformation test. Correlation was considered to be significant when the p-value was <0.05.
various cancer types. Particularly, the enzyme level of cervical cancer was similar to that we previously observed for healthy liver (data not shown). Many other cancer types expressed substantial level of this enzyme, median levels of which was 1/4-1/2 of that in the liver. In humans, 5-FUra would also be catabolized by tumor DPD as well as liver DPD. The DPD levels measured by the ELISA, in terms of protein concentrations, were slightly lower than those measured by the enzyme activity assay. This difference could be the result of protein concentrations of the samples prepared for these two assays. The tissue samples for the enzyme assay were dialyzed to remove natural substrates for DPD, so that their protein concentrations measured by a modified Lowry's method were lower than those for the ELISA assay. We also confirmed that dThdPase exists in tumor tissues from patients with various types of cancer. Tumor levels of dThdPase were several times higher than those in healthy tissues adjacent to tumors from our historical controls (data were not shown), as reported elsewhere (5) .
DPD is a rate-limiting enzyme for catabolizing uracil and its analogue 5-FUra. Deficiency of DPD therefore results in hyper-uracilnemia and increase of 5-FUra level in the plasma causing severe toxicity. On the other hand, a high expression level of DPD in a tumor tissue is reported to result in poor response to cancer therapy with 5- FUra (1-3) . In human cancer xenograft models, the dThdPase/DPD ratio in tumor tissues has been reported to correlate with the in vivo susceptibility to therapy with capecitabine and with its intermediate metabolite 5'-dFUrd (6) . DPD levels in tumors may be a useful para meter for predicting the efficacy of 5-FUra, and its prodrugs, particularly capecitabine and 5'-dFUrd. These two prodrugs are converted to 5-FUra by dThdPase preferentially in tumor tissues (9) , so that tumor levels of DPD as well as dThdPase may both be useful as parameters for predicting the efficacy of the two drugs.
The present study demonstrated tumor levels of DPD and dThdPase, and dThdPase/DPD ratios in various types of cancer, which would be helpful for understanding the efficacy of fluoropyrimidines. High levels of dThdPase/DPD in breast and colorectal cancers may explain the clinical efficacy of capecitabine in these cancer types (10, 11) . In addition, we observed the positive correlation between DPD and dThdPase levels in some cancer types, such as colorectal, pancreatic, esophageal, bladder, cervical, hepatic, and gastric cancers. Particularly, in colorectal cancer tissues, the correlation was much more evident (r=0.915, p<0.0001). dThdPase is known to be up-regulated by various factors, such as inflammatory cytokines (12) , growth factors, and other tumor tissue environment factors, while up-or downregulators for DPD expression have not yet been fully investigated. DPD and dThdPase expressions may be regulated in the above cancer types by common intrinsic factors present in the tumor tissues.
The differences in the median levels of DPD, dThdPase, and dThdPase/DPD among the cancer types studied were in the ranges of only 5-, 13-and 7-fold, respectively. In contrast, the inter-patient variances of tumor levels of DPD, dThdPase, and dThdPase/DPD were much larger than the variability among cancer types. Therefore, it would be difficult to predict the cancer-type susceptible to 5-FUra and its prodrugs only on the basis of tumor expression levels of either DPD, dThdPase, or dThdPase/DPD. However, the levels or the ratio of these enzymes in tumors may be useful for selecting patients who are likely to respond to fluoropyrimidines. Patients who have tumors with inappropriate levels of the enzyme expression would not respond to the fluoropyrimidines even if the tumors were included in the target indications approved. On the contrary, patients who have tumors with appropriate levels of the enzyme expression may respond to the drugs even if the tumor is not included as the approved indication for the drugs. The cancer profiling therapy, which is based on the tumor levels of DPD and dThdPase expression, would be a rational approach for optimizing therapy with fluoropyrimidines, such as 5'-dFUrd and capecitabine, which generate 5-FUra by dThdPase preferentially in tumors and are then catabolized by DPD in tumors. It would also be rational for combination therapy with the fluoropyrimidines and modulators of these enzymes (13) (14) (15) , or with DPD inhibitors.
